NCT06564584View on ClinicalTrials.gov

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
HypertriglyceridemiaNonalcoholic Fatty Liver Disease
Interventions
DRUG

TLC-2716 Dose 1

Capsules administered orally

DRUG

TLC-2716 Dose 2

Capsules administered orally

DRUG

Placebo

Capsules administered orally

Trial Locations (4)

14080

RECRUITING

OrsoBio Research Site, Mexico City

45116

RECRUITING

OrsoBio Research Site, Guadalajara

45170

RECRUITING

OrsoBio Research Site, Zapopan

06700

RECRUITING

OrsoBio Research Site, Mexico City

Sponsors

Lead Sponsor

OrsoBio, Inc
All Listed Sponsors
lead

OrsoBio, Inc

INDUSTRY

NCT06564584 - Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD | Biotech Hunter | Biotech Hunter